The limited effectiveness of therapy for patients with advanced stage head and neck squamous cell carcinoma (HNSCC) or recurrent disease is a reflection of an incomplete understanding of the molecular basis of HNSCC pathogenesis. MUC4, a high molecular weight glycoprotein, is differentially overexpressed in many human cancers and implicated in cancer progression and resistance to several chemotherapies. However, its clinical relevance and the molecular mechanisms through which it mediates HNSCC progression are not well understood. This study revealed a significant upregulation of MUC4 in 78% (68/87) of HNSCC tissues compared with 10% positivity (1/10) in benign samples (P = 0.006, odds ratio (95% confidence interval) = 10.74 (2.0-57.56). MUC4 knockdown (KD) in SCC1 and SCC10B HNSCC cell lines resulted in significant inhibition of growth in vitro and in vivo, increased senescence as indicated by an increase in the number of flat, enlarged and senescence-associated β-galactosidase (SA-β-Gal)positive cells. Decreased cellular proliferation was associated with G 0 /G 1 cell cycle arrest and decrease expression of cell cycle regulatory proteins like cyclin E, cyclin D1 and decrease in BrdU incorporation. Mechanistic studies revealed upregulation of p16, pRb dephosphorylation and its interaction with histone deacetylase 1/2. This resulted in decreased histone acetylation (H3K9) at cyclin E promoter leading to its downregulation. Orthotopic implantation of MUC4 KD SCC1 cells into the floor of the mouth in nude mice resulted in the formation of significantly smaller tumors (170 ± 18.30 mg) compared to those (375 ± 17.29 mg) formed by control cells (P = 0.00007). In conclusion, our findings showed that MUC4 overexpression has a critical role by regulating proliferation and cellular senescence of HNSCC cells. Downregulation of MUC4 may be a promising therapeutic approach for treating HNSCC patients.
INTRODUCTION
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer with approximately 650 000 incidences and 350 000 deaths worldwide annually. 1 In the United States, 41 380 new cases and 7850 HNSCC-related deaths were expected in 2013. 2 Despite multiple treatment modalities, including surgery, chemotherapy and/or radiotherapy, the 5-year survival rate has not improved beyond 40-50% in last three decades 3 and can be attributed to the incomplete understanding of the molecular basis of HNSCC pathogenesis. Therefore, unraveling the cellular pathways for improved understanding of HNSCC pathogenesis is urgently needed.
Mucins are a family of heavily O-glycosylated proteins protecting epithelial cell surfaces under normal physiological conditions. Several studies from our lab and others have identified mucins as potential tumor markers and attractive therapeutic targets. 4, 5 MUC4, a membrane-bound mucin is expressed in several normal tissues, but its expression is elevated in malignancies of ovaries, thyroid, pancreas and breast. 6 Studies from our lab have shown that ectopic overexpression of MUC4 induces neoplastic transformation of fibroblasts suggesting the oncogenic potential of MUC4. 7 MUC4 activates Src/focal adhesion kinase (FAK) signaling by physical interaction and stabilization of human epidermal growth factor receptor 2, 8, 9 thereby promoting survival, invasion and metastasis. 8, 9 More recently, we have shown that MUC4 stabilizes N-cadherin expression and promotes epithelial-to-mechenchymal transition in pancreatic cancer cells. 10 We studied MUC4 expression in human HNSCC tissues and investigated its functional role in HNSCC cell lines. We observed significant upregulation of MUC4 in HNSCC tissues compared with normal tissues. Knockdown (KD) of MUC4 in HNSCC cells reduced proliferation; led to cell cycle arrest and induced cellular senescence by modulating p16/Rb tumor-suppressor pathway. Furthermore, MUC4 KD decreased pRb and histone deacetylase 1/2 (HDAC1/2)-mediated histone acetylation (H3K9 acetylation) at cyclin E promoter resulting in transcriptional silencing of cyclin E. This study is the first to propose that MUC4 KD triggers a senescence response by regulating p16, cyclin D1 and cyclin E expression.
RESULTS
MUC4 is overexpressed in HNSCC tissues and cell lines Immunohistochemical analysis showed overexpression of MUC4 in 78% of the tumor samples compared with only 10% positivity in adjacent normal tissues [P = 0.006, odds ratio (95% confidence interval) =10.74 (2.0-57.56); Figure 1a ]. No significant association of MUC4 expression was observed with differentiation status, nodal metastasis, tumor size, age, gender and cigarette smoking ( Table 1) . HNSCC tissues showed a median composite score of 4 (range 0-12) for MUC4 as compared with the benign tissues with a median composite score of 0 (P = 0.01), as shown in the box plot analysis in Figure 1b . Receiver operating characteristic curve analysis was used to evaluate the potential of MUC4 protein as a biomarker for differentiating HNSCC from normal oral tissues. The value of area-under-the-curve calculated on the basis of total score obtained for immuno-staining of MUC4 protein was 0.78, with respect to normal tissues ( Supplementary Figure 1a) . These results suggest that MUC4 is deregulated in HNSCC tumors and raises the possibility that overexpression of MUC4 may contribute to pathogenesis of HNSCC.
We analyzed the expression of MUC4 in a panel of HNSCC cell lines and observed expression of MUC4 in 88% (7/8) of the cell lines at both RNA and protein level ( Figure 1c ). SCC1, SCC10B, SCC11B, SCC38, SCC47 and SCC74A showed robust expression of MUC4, while SCC23 cells showed mild expression at both RNA and protein level. SCC104 cells were negative for MUC4 expression ( Figure 1c ). MUC4 expression in HNSCC cell lines was independent of their site or origin, as cell lines derived from oral cavity (SCCI, SCC47 and SCC74A) and larynx (SCC10B and SCC11B) expressed similar levels of MUC4. Further, cell lines derived from both primary (SCC1, SCC38, SCC47 and SCC74) and recurrent metastatic tumors (SCC10B and SCC11B) showed similar MUC4 expression. We also did not observe any association between MUC4 expression and aggressiveness of the cells as very aggressive SCC1 and non-aggressive SCC10B cells 11 express equal amount of MUC4. In addition, highly aggressive SCC104 cells 12 did not express MUC4.
MUC4 silencing decreased cell proliferation and induced G 0 /G 1 cell cycle arrest in vitro To dissect its functional role in HNSCC pathogenesis, MUC4 was stably KD in SCC1 and SCC10B cells as previously described. 10 These two cell lines were selected because SCC1 cells are derived from the primary tumor in oral cavity with wild type but undetectable expression of p53, while SCC10B is derived from recurrent metastatic tissue in larynx with mutated and overexpressed p53 (Figure 3b ). Validation of MUC4 KD revealed a significant downregulation of MUC4 in shMUC4 SCC1 and SCC10B cells ( Figure 1d ). Further, real-time PCR and immunofluorescence analysis confirmed the MUC4 KD ( Supplementary Figures 2a  and b ).
To analyze the effect of MUC4 KD on proliferation of HNSCC cells, growth kinetics studies were performed. A significant decrease in growth rates of MUC4 KD SCC1 and SCC10B cells was observed (P = 0.004 and P = 0.015, respectively) ( Figure 2a ) indicating the role of MUC4 in cell proliferation. The doubling time increased from 26 to 36 h and 34 to 42 h in SCC1 and SCC10B cells, respectively, following MUC4 silencing. Similarly, MUC4 KD also notably reduced BrdU incorporation by 56% and 53% in MUC4 KD was observed in HNSCC with a median score of 4 (range 0-12), as compared with the histologically normal oral tissues with a median score of 0. (c) MUC4 expression in a panel of HNSCC cell lines was determined at protein level by immunoblotting, while mRNA was analyzed by reverse transcriptase (RT)-PCR. β-Actin was used as loading control for both western blot and RT-PCR analysis. (d) Silencing of MUC4 expression in SCC1 and SCC10B cells. Cells were infected with lentiviruses carrying short hairpin RNA (shRNA) against MUC4 in pLKO.1 hairpin vector or with scrambled sequence containing vector and used as control. Transfected cells were selected using Puromycin and positive clones were tested for MUC4 expression using 2% agarose sodium dodecyl sulfate (SDS) gel. β-Actin was used as a loading control. Figure 2c ). Furthermore, MUC4 KD reduced clonogenic potential (inhibiting colony formation) in both SCC1 and SCC10B cells. The number of colonies was reduced from 327 to 151 (54% decrease) and 233 to 125 (46% decrease) in SCC1 and SCC10B cells, respectively ( Figure 2b ). The number of larger colonies was reduced from 301/327 (92%) and 201/233 (86%) to 97/151 (64%) and 27/125 (21.6%) in SCC1 and SCC10B MUC4 KD cells, respectively.
SCC1 and SCC10B cells, respectively (Supplementary
To investigate the mechanism underlying the growth suppression of HNSCC cells following MUC4 KD, we performed cell cycle analysis of the MUC4 KD cells by fluorescence-activated cell sorting analysis. As shown in Figures 2c and d , MUC4 KD induced the G 1 arrest; the percentage of cells in G 1 phase increased from 70.9% to 81% (P = 0.05) and 69.9% to 82% (P = 0.02) and the percentage of cells in S phase decreased from 20% to 14.8% (P = 0.04) and 17.89% to 13.54% (P = 0.012) in SCC1 and SCC10B cells, respectively. However, MUC4 KD did not induce apoptosis in SCC1 and SCC10B cells, as demonstrated by the lack of sub-G 1 peak and annexin-V-positive cells (Figures 2c and d) and ( Supplementary Figures 3a and b ) and absence of any change in expression of Bcl2 and caspase-9 expression ( Supplementary  Figure 3b ). MUC4 KD reduces motility/invasive potential in HNSCC cells MUC4 KD has been shown to decrease cell motility and invasion in various cancer cells. [8] [9] [10] We analyzed the motility of MUC4 KD SCC1 and SCC10B cells by Transwell migration (Boyden chamber) and scratch assay and observed a significant decrease in motility (P o 0.001 and Po 0.002) of MUC4 KD cells compared with control cells ( Supplementary Figures 4a and b ), respectively. We also observed a concordant decrease in invasive capability of MUC4 KD cells compared with control cells (P o 0.005 and P o 0.004, respectively) ( Supplementary Figure 4c) .
FAK, a non-receptor protein-tyrosine kinase is involved in cellular motility and invasion. Src-mediated phosphorylation and activation of FAK is required for focal adhesion assembly and cell spreading. Therefore, we determined if the decreased motility and invasion following MUC4 KD is mediated through Src/FAK signaling. We observed decreased phosphorylated Src and FAK in both SCC1 and SCC10B MUC4 KD cells compared with control cells ( Supplementary Figure 4d ) signifying the importance of Src/FAK pathway in MUC4-mediated increased cellular motility and invasion.
MUC4 silencing induces senescence in HNSCC cells
Cell cycle arrest is the central feature of senescent cells in vitro and in vivo. Morphologically, MUC4 KD SCC1 and SCC10B cells were vacuolated, flattened and much larger in size as compared with control cells (Figure 3a ), a characteristic phenotype of senescent cells. 13 To test whether MUC4 KD-induced cell cycle arrest was accompanied by senescence induction, we examined the expression of senescence-associated β-galactosidase (SA-β-gal) activity and senescence-associated heterochromatin foci (SAHF), which are markers for cellular senescence, in MUC4silenced and control cells. Our SA-β-gal staining showed 37 ± 4% and 27 ± 6% positivity in MUC4 KD SCC1 and SCC10B cells compared with 3 ± 2% and 4 ± 1% in control cells, respectively ( Figure 3a ). Furthermore, 4, 6-diamidino-2-phenylindole-stained nuclei in MUC4 KD cells showed distinct SAHF compared with control cells as observed by immunofluorescence microscopy (Figure 3a ). Overall, these results indicate that MUC4 KD leads to cell cycle arrest and senescence.
MUC4 modulates phosphatidylinositol 3 kinase/Akt and extracellular signal-regulated kinases 1 and 2 (ERK1/2) signaling pathways in several cancers, 9, 10, 14 and these pathways are important in regulating cellular senescence. 15, 16 Our results revealed decreased levels of pAkt at Thr-308/Ser-473 and pERK1/2 in MUC4 KD SCC1 and SCC10B cells compared with control cells (Figure 3b ) suggesting that MUC4 depletion induces cellular senescence by inactivation of phosphatidylinositol 3 kinase/Akt or ERK1/2 signaling pathways. No change in expression of total Akt and ERK1/2 was observed.
MUC4 KD induces senescence through p16/pRb pathway p16/pRb and p53/p21 pathways are master regulators of cell cycle progression and cell senescence. 17 The effect of MUC4 KD on delayed G 1 /S progression and induction of senescence prompted us to examine the expression of key molecules controlling G 1 /S transition. We observed significant upregulation of p16 protein and downregulation of cyclin E, cyclin D1, decreased phosphorylation of pRb in MUC4 KD cells compared with control cells (Figure 3b ). However, no changes in the expression of p21 and p27 were observed ( Figure 3b ).
Upregulation of p16 in MUC4 KD cells suggested p16-mediated senescence in HNSCC cells. To directly establish the role of p16 in senescence, we silenced p16 expression by p16-specific small interfering RNA in MUC4 KD cells. We observed a significant downregulation of p16 after 72 h of transfection in MUC4 KD cells compared with control small interfering RNA-transfected cells ( Figure 3c ). We also observed a clear rescue of the morphological effects of MUC4 KD with a significant reduction in SA-β-Galpositive cells among small interfering RNA-transfected MUC4 KD SCC1 (9 ± 3%) and SCC10B (8 ± 4%) as compared with scrambled oligos transfected MUC4 KD SCC1 (39 ± 4%) and SCC10B (32 ± 6%) cells ( Figure 3d ). Importantly, the level of cyclin E, which is known to be expressed during G 1 /S transition and peak in the S phase and was noted to be downregulated in MUC4-silenced cells, was fully restored in p16 and MUC4 double KD ( Figure 3c ) SCC1 and SCC10B cells. These results suggest that MUC4 KD induces a p16/ Rb-dependent cellular senescence to suppress the growth of HNSCC cells.
MUC4 KD induces chromatin remodeling to downregulate cyclin E expression SAHF formation during cellular senescence is accompanied by loss of heterochromatin markers like Lys9 tri-methyl (H3K9me3), H3K27me3 of histone H3 and exclusion of euchromatic markers histone H3K9 acetyl, H3K4me2 and H3K4me3 on promoters of various cell cycle genes. 18 Histone acetylation/de-acetylation on promoter has been shown to regulate cyclin E expression. 19 MUC4 KD resulted in decreased acetylated H3K9 and H3K4me2 with concomitant increase in H3K27me3 compared control cells ( Figure 4a ). However, no change in acetylated H2BK5 H2AK5 was observed in MUC4 KD cells as compared to control cells. Furthermore, the ratio of H3K4me2 to H3K27me3 shifted more towards the inactive chromatin in MUC4 KD cells with respect to control cells ( Supplementary Figure 5a) suggesting that deregulation of cell cycle-regulated genes particularly cyclin E may be due to heterochromatin formation. Differential binding of histone acetyl transferases and HDACs regulate cyclin E promoter activity. 20 Hypophosphorylated Rb interacts with HDAC 1, 2 and 3 and recruits them to the promoters of E2F target genes leading to repression of their expression. 18 To investigate the role of HDAC1/2 and Rb in senescence, we immunoprecipitated Rb complexes from MUC4 KD SCC1, SCC10B and observed increased levels of HDAC1/2 bound to unphosphorylated Rb in MUC4 KD cells compared with control cells (Figure 4b ) indicating the involvement of HDAC 1 and 2-mediated cyclin E downregulation. More pronounced interaction between Rb and HDAC2 was observed in MUC4 KD cells as compared between HDAC1 and Rb. To further confirm the involvement of HDACs, we treated MUC4 KD cells with 5 μM Trichostatin A, an HDAC inhibitor for 48 h and observed the re-expression of cyclin E compared with untreated MUC4 KD cells (Figure 4c ). But on the contrary, we observed increased SA-β-gal-stained cells (Figure 4c ). Therefore, we investigated if MUC4-mediated cyclin E downregulation was due to loss of acetylated chromatin on its promoter by performing chromatin immunoprecipitation assay using antiacetylated histone H3 antibody. The H3 occupancy at E2F consensus binding sites of cyclin E promoter was analyzed using specific primers spanning the nucleotides between 1098 and 1795 bp on cyclin E promoter. 21 Less acetylated histone H3 was observed on the cyclin E promoter in both SCC1 and SCC10B MUC4 KD cells as compared with the control cells ( Figure 4d ) confirming that cyclin E downregulation upon MUC4 KD is mediated by histone deacetylation and heterochromatin formation. Association of pRb and HDAC1/2 was studied in the lysates of control and MUC4 KD SCC1 and SCC10B cells by immunoprecipitation and western blotting as described in Materials and methods section. HDAC 1 and 2 were immunoprecipitated using specific antibodies and the bound levels of pRb co-precipitated with HDAC1/2 were determined by western blot analysis. (c) Trichostatin A (TSA) treatment induces cyclin E expression and increases SA-β-gal-stained cells. MUC4 KD SCC1 and SCC10B cells were treated with TSA (5 μM) and 48 h and protein lysates were analyzed by western blot analysis and probed with cyclin E, cyclin D1 and acetylated H3K9 specific antibodies. β-Actin was used as a loading control. Similarly, TSA-treated cells were analyzed for SA-β-gal staining and senescent cells were observed and counted. (d) Decreased H3K9 acetylation at cyclin E promoter. Cross-linked, sheared chromatin was prepared from control and MUC4 KD SCC1 and SCC10B cells and subjected to immunoprecipitation with the H3K9 acetylated antibody. The immunoprecipitated complexes were subjected to PCR analysis using primer pairs spanning the human cyclin E promoter. Mouse IgG was used as negative control, whereas chromatin obtained before immunoprecipitation was used as internal control. 14, 55 have shown that MUC4 via physical interaction and subsequent stabilization of human epidermal growth factor receptor 2 (HER2)/ErbB2 leads to activation of Src/FAK, phosphatidylinositol 3 kinase (PI3K)/Akt and ERK signaling pathways for enhanced motility, viability and increased cell proliferation.
MUC4 KD suppresses tumorigenicity in vivo MUC4 KD HNSCC cells were less proliferative, migratory and invasive in vitro; we thus tested if our in vitro observations correlated with tumorigenicity and metastasis in vivo. We orthotopically implanted (2.5 × 10 5 in 50 μl of phosphatebuffered saline) either SCC1 MUC4 KD or control cells/animal into the floor of mouth in nude mice (seven mice per group). As a result of the large tumors formed by controls cells, animals were euthanized 15 days post implantation, whereas animals implanted with MUC4 KD cells formed relatively smaller tumors and were euthanized 30 days after implantation. Tumors formed by control cells were significantly larger (median weight of 375 ± 17.29 mg) than MUC4 KD cells (170 ± 18.30 mg; P = 0.00007) (Figure 5a ) indicating that KD of MUC4 in HNSCC cells decreased tumorigenicity. Immunohistochemical analysis of the harvested tumors revealed decreased MUC4 expression compared with control animals, indicating that MUC4 KD was maintained in vivo ( Figure 5b ). Furthermore, reduced Ki-67-positive cells were observed in tumors from MUC4 KD implanted animals compared with control cells (Figure 5b ). Similar to the in vitro observations, we also noted increased p16 expression and decreased cyclin E expression in tumors from MUC4 KD cells compared with control cells (Figure 5b) . Further, the percentage of SA-β-gal-positive cells was higher (~70%) in tumors from MUC4 KD cells as compared with control cells (~15%) (Figure 5c ), strongly indicating cellular senescence in vivo is driven by MUC4 KD. Overall, our results suggest that MUC4 KD significantly suppressed tumor size by inhibiting proliferation and inducing cellular senescence in vivo.
DISCUSSION
MUC4 has recently emerged as a useful diagnostic marker and potential target for therapeutic intervention in several malignancies because of its functional involvement in promoting cell proliferation, invasion, metastasis and inhibition of apoptosis. 9, 14, [22] [23] [24] Several studies have reported aberrant expression of mucins (MUC1, MUC2, MUC4 and MUC5AC), but no functional study has yet been reported in HNSCC. [25] [26] [27] [28] [29] Using 1G8 antibody, MUC4 overexpression has been reported in HNSCC (oral cavity, oropharynx, larynx and hypopharynx) and associated with a worse prognosis. 27 However, head-to-head comparison of 1G8 with Mab 8G7, which recognizes human MUC4 has conclusively demonstrated that 1G8 neither recognizes human MUC4, nor exhibits staining pattern similar to human MUC4 antibody. 30, 31 A recent study using MAb 8G7 reported MUC4 overexpression (58%) in oral squamous cell carcinoma (OSCC) and its association with higher T classification, positive nodal metastasis, advanced tumor stage, diffuse invasion of cancer cells and bad prognosis. 29 In accordance with this report, we also observed a significant upregulation of MUC4 (78%) in HNSCC tissues compared with benign samples (P = 0.006), but did not find significant association of MUC4 overexpression with any clinical or pathological characteristics of patients ( Figure 1 and Table 1 ). The major difference between the two studies was that we analyzed tissues samples of HNSCC, which includes oral cavity, oropharynx, larynx and hypopharynx, whereas the previous study used tissues from oral cavity only. The lack of comprehensive knowledge about mucins prompted us to analyze the clinical and functional significance of mucins particularly MUC4 in HNSCC.
Our functional analysis using gene silencing approach indicated that MUC4 is involved in the regulation of cell growth, motility and invasion of HNSCC cells. We have previously demonstrated that MUC4 upregulates N-cadherin expression, which in turn interacts and stabilizes FGFR1 thereby promoting epithelial-tomesenchymal transition and therefore aggressive metastatic behavior of pancreatic cancer cells. 10 Further, previous studies in breast, ovarian and pancreatic cancers have established that MUC4 interacts with and stabilizes human epidermal growth factor receptor 2, also known as ErbB2 leading to Src, FAK, Akt and ERK activation implicated in cell survival, cell motility/invasion and metastasis. 8, 10, 14, 32, 33 Similarly, in this study, MUC4 KD in HNSCC cells resulted in decreased phosphorylation of Src, FAK, Akt and ERK and resulted in decreased proliferation, motility and invasion ( Supplementary Figures 4a and d) . Further, we observed that MUC4 augments proliferation by modulating cell cycle regulatory proteins like p16, cyclin E and cyclin D1. MUC4 silencing suppressed growth via a unique mechanism involving G 0 /G 1 cell cycle arrest. Interestingly, MUC4 silencing in HNSCC cell lines resulted in cellular senescence as suggested by large and flat cell morphology, increased SA-β-Gal-stained cells and SAHF formation (Figure 3a) , which are considered to be characteristics of senescent cells. 34 This is the first report demonstrating that MUC4 expression augments senescence in cancer cells.
Cellular senescence is a potent tumor-suppressor mechanism preventing unregulated growth and malignant transformation. p53 and p16/Rb signal transduction cascades are the master regulators for cell cycle and promotion of cellular senescence. 35 Often lost in a variety of malignancies, p16 acts as an allosteric inhibitor of cdk4/6 complex to prevent its interaction with cyclin D1, inducing the cell cycle arrest and senescence by activating Rb pathway. Cdk4/6-cyclin D1 complex-mediated phosphorylation and inactivation of Rb allows the transcription of E2F-dependent various cell cycle regulatory genes including cyclin E. MUC4 silencing-induced cellular senescence in HNSCC cells in a p16dependent manner as indicated by: (a) increased p16 expression in MUC4 KD cells (b) abrogation of MUC4 silencing-induced senescence phenotype following p16 KD (Figures 3c and d) . Our studies further indicated that senescence induction in MUC4 KD cells involved pRb dephosphorylation and chromatin remodeling to regulate cell cycle regulating protein cyclin E (Figures 3b and  4a-d) . Both P53 and p16/Rb signaling pathways are disrupted in 60-70% of HNSCC patients either by mutation, gene disruption or by promoter hypermethylation. 36, 37 Although the involvement of p16 in cellular senescence and its downregulation in HNSCC is well established, there is still lack of a comprehensive study of its role in HNSCC senescence. Overexpression of p16 and p53 induced growth arrest of HNSCC cells 38 , suggesting that p53 or p16 restoration would be enough to decrease cell proliferation and tumor growth. Intriguingly, MUC4 silencing-induced senescence seemed to occur in a p53-independent manner as MUC4 KD induced growth arrest and senescence in both SCC1 and SCC10B cells (Figure 3b ). Furthermore, western blot analysis revealed no difference in the expression level of p53 between MUC4 KD and control shRNA transfected cells (Figure 3b ). Besides the p53 and p16/Rb pathway, phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is also involved in the decision making and maintenance of oncogene-driven senescence; however, no change in PTEN expression in MUC4 KD cells suggested the involvement of only p16/Rb pathway in senescence induction on MUC4 KD (Figure 3b ).
Increased proliferation is mostly driven by altered cell cycle progression. 32 In HNSCC, cyclin E overexpression 39 has been shown to promote G 1 to S phase transition and induce escape from Ras-induced senescence in mouse embryonic fibroblasts. 40 Conversely, a decrease in cyclin E-Cdk2 activity results in inhibition of the G 1 to S phase transition and induction of senescence. 19 Silencing of MUC4 resulted in decreased proliferation and G 0 /G 1 cell cycle arrest, providing evidence that MUC4 is a modulator of the cell cycle (Figures 2a-d) . The decreased proliferation and cell cycle arrest was associated with downregulation of cell cycle regulatory proteins such as cyclin E and cyclin D1 (Figure 3b ). Previously, we have shown G 0 /G 1 cell cycle arrest and decreased proliferation upon MUC4 KD in breast and pancreatic cancer cells. 14, 41 In contrast to oncogenic role of MUC4 in PC, ovarian and breast, our recent work has shown a tumor-suppressor role of MUC4 in lung cancer with decreased proliferation and induction of G 2 /M cell cycle arrest upon MUC4 overexpression 42 along with downregulation of cyclin A, cyclin D1 and upregulation of cyclindependent kinase inhibitors p21 and p27, suggesting that MUC4 has the potential to regulate (that is, either promote or suppress) proliferation by altering cell cycle regulatory proteins. 42 In accordance with all these observations, we also observed increased expression of p16 and decreased expression of pRb, cyclin D1 and cyclin E expression upon KD of MUC4 in HNSCC cells and it appears that cyclin E/D downregulation appears to be a direct consequence of MUC4 depletion (Figure 3b ).
Local perturbations of chromatin structure could alter the accessibility and/or function of transcriptional regulatory proteins that bind DNA sequences in the region where histone acetylation or de-acetylation occurs. 8, 43 Previous studies have shown that p300 downregulation decreased cyclin E expression through decreased histone acetylation and increased methylation of cyclin E promoter at the E2F-binding site 19 leading to chromatin rearrangement accompanied by SAHF. 8, 18 As seen by 4, 6-diamidino-2-phenylindole staining, we also observed numerous SAHF in MUC4 KD cells compared with control cells (Figure 3a ) suggesting that heterochromatin modification may be involved in cyclin E downregulation. These SAHF were shown to be enriched in heterochromatin markers like Lys9 tri-methyl (K9me3), H3K27me3 and heterochromatin protein 1 of histone H3, and excluded euchromatic markers, such as histone H3K9 acetyl and H3K4me3. 18 Acetylation and methylation of H3K9 are mutually exclusive and therefore de-acetylation of H3K9 by HDAC, which leads to repression, also allows for H3K9 methylation by methyltransferases like Suv39H. 44 Similarly, our results revealed that MUC4 KD in HNSCC cells resulted in decreased expression of acetylated H3K9 and increased expression of H3K27me3 compared with control cells (Figure 4a ) with no global changes in expression of acetylated H2BK5 and H2AK5. Ratios of H3K4me3/ H3K27me3 were also decreased in MUC4 KD cells than the control cells. Similar to this observation, an earlier study has also shown the differential gene expression upon either H3K4me3/H3K27me3 methylation. 45 Histone modification at cyclin E promoter and its associated downregulation was further confirmed by chromatin immunoprecipitation assay using H3K9 acetylated antibody. In accordance with the results obtained by Bandyopadhyay et al. 19 in human melanocytes that decreased acetylated histone at the cyclin E promoter resulted in decreased cyclin E expression, we also observed cyclin E downregulation by MUC4 mediated reduced H3K9 acetylation (Figure 4d ). Under-phosphorylated pRb can recruit HDAC 1, 2 and 3 to E2F-dependent promoters like cyclin E, de-acetylating nearby histones and repressing gene expression. 46, 47 So we investigated whether HDAC may be involved in de-acetylating H3K9 at cyclin E promoter. Coimmunoprecipitation and immunoblot analysis showed increased association between Rb and HDAC1 and HDAC2 in MUC4 KD cells compared to control cells with no change in total HDACs (Figure 4b ). HDAC inhibitor Trichostatin A has been shown to abolish Rb repression on some E2F target promoters like cyclin E. 19 Although Trichostatin A treatment to the MUC4 KD cells induced cyclin E expression comparable to control cells (Figure 4c) , we observed increased SA-β-gal staining cells (Figure 4c) . A likely explanation could be the necessity of the cells to maintain a critical balance between acetylated and de-acetylated chromatin domains to sustain proliferation. 19 Although hyper-acetylation caused by the loss of HDAC activity could activate anti-proliferative genes, loss of acetylation may shift the balance toward repressive heterochromatin, causing silencing of genes associated with cell cycle progression.
Human papillomavirus (HPV) is an important etiological factor for oropharyngeal cancers among head and neck cancers. 48 These tumors have distinct molecular profile and significantly better prognosis than the traditional HPV-negative and tobacco and alcohol-related cancers. 49 Recently, exome sequencing revealed several mutations in MUC4 as well as in other mucins including MUC6 and MUC16 in HPV-positive tumors compared with HPV-negative tumors. 50, 51 Although functional impact of these mutations remain undetermined, it is possible that these mutations may affect mucin expression, stability and posttranslational modifications. Although it is of interest to determine MUC4 expression in the context of HPV infections particularly in oropharyngeal cancer, owing to small sample size and unknown HPV status such correlations could not be investigated in this study. However, we plan to study this association in a large cohort of oropharyngeal patients in future.
Overall, we have shown that MUC4 KD inhibits cell proliferation both in vitro and in vivo through induction of senescence programming pathways (Figure 5d ). Several studies have shown that loss of oncogene function induces cellular senescence. 19, 52 KD of MUC4 is crucial for ensuring the irreversibility of the senescence arrest even in p53 mutant cells. Our findings not only offer new perspectives in the modulation of senescence by MUC4 but also provide strong evidence for MUC4 based therapeutic interventions in HNSCC patients.
MATERIALS AND METHODS

Chemicals and antibodies
Trichostatin A was purchased from Cayman Chemicals (Ann Arbor, MI, USA). The protein assay kit was from Bio-Rad (Hercules, CA, USA). Annexin-V-conjugated AlexaFluor488 Apoptosis Detection Kit from Molecular Probes, Inc., (Eugene, OR, USA). p16 small interfering RNA was purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). MUC4 monoclonal antibody (8G7) was developed in our laboratory. 53 Horseradish peroxidase-conjugated anti-mouse and anti-rabbit immunoglobulin G were procured from GE Healthcare Biosciences (Uppsala, Sweden) and fluorescein isothiocyanate-conjugated anti-mouse immunoglobulin G was obtained from Invitrogen (Carlsbad, CA, USA). All other antibodies used are listed in Supplementary Table 1 .
Cell culture and MUC4 KD
Head and neck cancer cell lines UMSCC1, UMSCC10B, UMSCC11B, UMSCC23, UMSCC38, UMSCC47, UMSCC74 and UMSCC104 were a kind gift from Dr Thomas Carey (University of Michigan, Ann Arbor, MI, USA) and maintained as described in previous reports. 54 Stable MUC4 KD HNSCC cells were generated as described previously. 8 Stable MUC4 short hairpin RNA or scramble-transfected clones were selected, pooled and tested for MUC4 expression by real-time PCR10, confocal microscopy 33 and by western blot analysis. 54 Co-immunoprecipitation assay was done as previously described. 55 Cell proliferation, colony formation and BrdU incorporation For growth rate analysis, 1 × 10 3 cells per well were grown in 1% α-minimum essential medium and viable cell numbers were determined every 24 h for 8 days using a Vi-Cell XR instrument (Beckman Coulter, Fullerton, CA, USA). Cell proliferation was also determined by measuring the incorporation of BrdU using a BrdU In-Situ Detection Kit (BD Pharmingen, San Diego, CA, USA). In brief, control and MUC4 KD (10 × 10 3 ) cells were incubated overnight with 10 μM BrdU for 24 h at 37°C
. The incorporated BrdU was detected with a horseradish peroxidaseconjugated anti-BrdU antibody and using tetramethylbenzidine as a substrate. After stopping the reaction with H 2 SO 4 , plate was read at 450 nm. Effect of MUC4 KD on cell cycle, in vitro colony formation, cell motility and invasion was done as described by us previously. 42, 54 Quantitative in situ SA-β-gal assay SA-β-gal activity was measured according to the manufacturer's instructions (Cell Signaling Technology, Beverly, MA, USA). SA-β-Gal activity was detected using X-gal (5-bromo-4-chloro-3-indolyl β-D-galactoside) staining at pH 6.0. Using light microscope, several representative fields (n = 10) were randomly selected for the quantification of the percentage of SA-β-gal-positive cells. Similarly, frozen tumor tissues from mice were stained for SA-β-gal activity as above.
Tumorigenicity assay
Control and MUC4 KD SCC1 cells of >97% viability (2.5 × 10 5 cells per 50 μl) were orthotopically implanted at the floor of mouth (seven animals per group). 56 Athymic nude mice were purchased from the Harlan laboratories (Denver, CO, USA). The mice were treated in accordance with Institutional Animal Care and Use Committee of UNMC guidelines. Based on the size of the tumor, mice bearing control cells were euthanized after 15 days of implantation, whereas MUC4 KD implanted mice were euthanized after 30 days. Tumors were excised, weighed, measured and formalin fixed. A part of the tumor tissue was also snap-frozen for SA-β-gal analysis. Experiment was repeated twice.
Immunohistochemistry
The study was approved by the institutional review board of University of Nebraska Medical Center, Omaha, NE, USA. Eighty-seven primary HNSCC samples and 10 benign tissues were analyzed by immunohistochemical analysis for MUC4 as described previously. 14 Tumors from orthotopically implanted animals were also analyzed for MUC4, p16, cyclin E and Ki-67 expression. Anti-KLH Mab K2G6 was used as negative control. Slide were analyzed by two pathologists (SML and SLJ) blinded to the study. Intensity of expression and percentage of cells stained were analyzed and overall staining was then represented by a composite score as done by us earlier. 14 
Statistical analysis
The data were analyzed using the Medcalc software (version 9.6.4.0) for windows (MedCalc Software, Mariakerke, Belgium). The relationship between MUC4 protein expression and clinicopathological parameters was tested using Chi-Square and Fisher's test. Mean tumor weights were compared between groups using a two-tailed independent sample Student's t-test. The criterion for statistical significance was *Po0.05, **Po0.01 and ***P o0.005.
